Active immunotherapy with B.C.G. for recurrent malignant melanoma. 1973

J U Gutterman, and G Mavligit, and C McBride, and E Frei, and E J Freireich, and E M Hersh

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008722 Methods A series of steps taken in order to conduct research. Techniques,Methodological Studies,Methodological Study,Procedures,Studies, Methodological,Study, Methodological,Method,Procedure,Technique
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females

Related Publications

J U Gutterman, and G Mavligit, and C McBride, and E Frei, and E J Freireich, and E M Hersh
January 1975, Panminerva medica,
J U Gutterman, and G Mavligit, and C McBride, and E Frei, and E J Freireich, and E M Hersh
January 1975, Panminerva medica,
J U Gutterman, and G Mavligit, and C McBride, and E Frei, and E J Freireich, and E M Hersh
March 1978, British medical journal,
J U Gutterman, and G Mavligit, and C McBride, and E Frei, and E J Freireich, and E M Hersh
May 1973, Lancet (London, England),
J U Gutterman, and G Mavligit, and C McBride, and E Frei, and E J Freireich, and E M Hersh
January 1989, Seminars in surgical oncology,
J U Gutterman, and G Mavligit, and C McBride, and E Frei, and E J Freireich, and E M Hersh
August 1997, Harefuah,
J U Gutterman, and G Mavligit, and C McBride, and E Frei, and E J Freireich, and E M Hersh
June 1975, Biomedicine / [publiee pour l'A.A.I.C.I.G.],
J U Gutterman, and G Mavligit, and C McBride, and E Frei, and E J Freireich, and E M Hersh
November 1975, Lijecnicki vjesnik,
J U Gutterman, and G Mavligit, and C McBride, and E Frei, and E J Freireich, and E M Hersh
September 1981, Schweizerische medizinische Wochenschrift,
J U Gutterman, and G Mavligit, and C McBride, and E Frei, and E J Freireich, and E M Hersh
January 1977, Oncology,
Copied contents to your clipboard!